Galapagos (NASDAQ:GLPG) Shares Pass Above Two Hundred Day Moving Average – Here’s Why

Galapagos NV (NASDAQ:GLPG) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $26.12 and traded as high as $28.43. Galapagos shares last traded at $28.22, with a volume of 367,224 shares traded.

Analyst Ratings Changes

Separately, Wall Street Zen cut Galapagos from a “hold” rating to a “sell” rating in a report on Friday, April 25th. Five analysts have rated the stock with a sell rating and four have given a hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $25.33.

Galapagos Trading Up 1.1%

The stock has a fifty day moving average of $27.17 and a two-hundred day moving average of $26.12.

Galapagos (NASDAQ:GLPG) last announced its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($2.24). The business had revenue of $97.33 million during the quarter, compared to analysts’ expectations of $72.22 million. Equities analysts anticipate that Galapagos NV will post -1.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Wealthquest Corp bought a new position in Galapagos in the 1st quarter valued at $74,000. BNP Paribas Financial Markets boosted its position in Galapagos by 45.9% in the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 2,824 shares during the last quarter. GAMMA Investing LLC boosted its position in Galapagos by 354.5% in the 1st quarter. GAMMA Investing LLC now owns 10,148 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 7,915 shares during the last quarter. QRG Capital Management Inc. boosted its position in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 1,866 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC bought a new position in Galapagos in the 4th quarter valued at $311,000. 32.46% of the stock is currently owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.